This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Webinars/Videos
Infographics
Articles
Case Studies
Forum
Faculty
Unblocked
Stay up to date

Clinical Research and Guidelines Articles

Articles
Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association
Agarwala A, Dixon DL, Gianos E, et al.
Journal:
J Clin Lipidol

First published: May 30, 2024 DOI: 10.1016/j.jacl.2024.05.005
View
- Share
Articles
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
Wright RS, Raal FJ, Koenig W, et al.
Journal:
Cardiovasc Res

First published: May 16, 2024 DOI: 10.1093/cvr/cvae109
View
- Share
Articles
Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use
Soroosh GP, Tasdighi E, Adhikari R, et al.
Journal:
Prog Cardiovasc Dis

First published: May 15, 2024 DOI: 10.1016/j.pcad.2024.05.004
View
- Share
Articles
Empagliflozin after Acute Myocardial Infarction
Butler J, Jones WS, Udell JA, et al.
Journal:
N Engl J Med

First published: April 25, 2024 DOI: 10.1056/NEJMoa2314051
View
- Share
Articles
Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial
Sayed A, Brophy JM
Journal:
Int J Cardiol

First published: April 19, 2024 DOI: 10.1016/j.ijcard.2024.132074
View
- Share
Articles
Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease
Holtrop J, Bhatt DL, Ray KK, et al.
Journal:
Eur J Prev Cardiol

First published: April 18, 2024 DOI: 10.1093/eurjpc/zwae038
View
- Share
Articles
The ’10 commandments’ for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Schütt K, Federici M, Verket M, et al.
Journal:
Eur Heart J

First published: April 14, 2024 DOI: 10.1093/eurheartj/ehad881
View
- Share
Articles
Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial
Nissen SE, Wolski K, Watts GF, et al.
Journal:
JAMA

First published: April 9, 2024 DOI: 10.1001/jama.2024.4504
View
- Share
Articles
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Koschinsky ML, Bajaj A, Boffa MB, et al.
Journal:
J Clin Lipidol

First published: March 29, 2024 DOI: 10.1016/j.jacl.2024.03.001
View
- Share
Articles
Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN
Reijman MD, Kusters DM, Groothoff JW, et al.
Journal:
Atherosclerosis

First published: March 27, 2024 DOI: 10.1016/j.atherosclerosis.2024.117525
View
- Share
Articles
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study
Alonso R, Arroyo-Olivares R, Díaz-Díaz JL, et al.
Journal:
Atherosclerosis

First published: March 16, 2024 DOI: 10.1016/j.atherosclerosis.2024.117516
View
- Share
Articles
Oral PCSK9 Inhibitors
Agarwala A, Asim R, Ballantyne CM
Journal:
Curr Atheroscler Rep

First published: March 13, 2024 DOI: 10.1007/s11883-024-01199-2
View
- Share

1 2 3 … 5

How would you rate this content?

Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.

Clinical Research and Guidelines Articles

Articles

Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association

Agarwala A, Dixon DL, Gianos E, et al.

Articles

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright RS, Raal FJ, Koenig W, et al.

Articles

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Soroosh GP, Tasdighi E, Adhikari R, et al.

Articles

Empagliflozin after Acute Myocardial Infarction

Butler J, Jones WS, Udell JA, et al.

Articles

Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial

Sayed A, Brophy JM

Articles

Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease

Holtrop J, Bhatt DL, Ray KK, et al.

Articles

The ’10 commandments’ for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

Schütt K, Federici M, Verket M, et al.

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Articles

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice

Koschinsky ML, Bajaj A, Boffa MB, et al.

Articles

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN

Reijman MD, Kusters DM, Groothoff JW, et al.

Articles

Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

Alonso R, Arroyo-Olivares R, Díaz-Díaz JL, et al.

Articles

Oral PCSK9 Inhibitors

Agarwala A, Asim R, Ballantyne CM

Articles

Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association

Agarwala A, Dixon DL, Gianos E, et al.

Share

Articles

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright RS, Raal FJ, Koenig W, et al.

Share

Articles

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Soroosh GP, Tasdighi E, Adhikari R, et al.

Share

Articles

Empagliflozin after Acute Myocardial Infarction

Butler J, Jones WS, Udell JA, et al.

Share

Articles

Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial

Sayed A, Brophy JM

Share

Articles

Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease

Holtrop J, Bhatt DL, Ray KK, et al.

Share

Articles

The ’10 commandments’ for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

Schütt K, Federici M, Verket M, et al.

Share

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Share

Articles

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice

Koschinsky ML, Bajaj A, Boffa MB, et al.

Share

Articles

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN

Reijman MD, Kusters DM, Groothoff JW, et al.

Share

Articles

Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

Alonso R, Arroyo-Olivares R, Díaz-Díaz JL, et al.

Share

Articles

Oral PCSK9 Inhibitors

Agarwala A, Asim R, Ballantyne CM

Share